{"id":8165,"date":"2025-04-09T10:43:54","date_gmt":"2025-04-09T07:43:54","guid":{"rendered":"https:\/\/www.sakiaivsb.lt\/?p=8165"},"modified":"2025-04-09T10:43:54","modified_gmt":"2025-04-09T07:43:54","slug":"pradedami-kompensuoti-nauji-vaistai-nuo-vezio","status":"publish","type":"post","link":"https:\/\/www.sakiaivsb.lt\/?p=8165","title":{"rendered":"Pradedami kompensuoti nauji vaistai nuo v\u0117\u017eio"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Privalomojo sveikatos draudimo fondo (PSDF) l\u0117\u0161omis nuo \u0161iol bus kompensuojami nauji vaistai, skirti \u012fvairi\u0173 form\u0173 v\u0117\u017eiui gydyti.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201eSveikatos apsaugos ministerija kartu su Valstybine ligoni\u0173 kasa ir Valstybine vaist\u0173 kontrol\u0117s tarnyba deda visas pastangas, kad nauji veiksmingi vaistai nuo v\u0117\u017eio kuo grei\u010diau pasiekt\u0173 pacientus. Glaudus institucij\u0173 bendradarbiavimas padeda spar\u010diau \u012fgyvendinti teis\u0117s akt\u0173 reikalavimus ir \u012ftraukti \u0161iuos vaistus \u012f kompensavimo sistem\u0105\u201c, \u2013 teigia sveikatos apsaugos viceministras Daniel Naumovas.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">I\u0161 rezervinio vaist\u0173 s\u0105ra\u0161o \u012f kompensuojam\u0173j\u0173 vaist\u0173 s\u0105ra\u0161\u0105 perkelti darolutamidas, olaparibas, pembrolizumabas, abemaciklibas ir trastuzumabo derukstekanas. \u0160ie vaistai pad\u0117s pacientams, sergantiems kr\u016bties, prostatos, gimdos kaklelio ir stempl\u0117s bei gastroezofagin\u0117s jungties v\u0117\u017eiu.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201e\u012e kompensuojam\u0173j\u0173 vaist\u0173 s\u0105ra\u0161\u0105 \u012ftraukiami itin svarb\u016bs vaistai, kurie anks\u010diau buvo rezerviniame s\u0105ra\u0161e ir lauk\u0117 finansavimo. Tai gera \u017einia t\u016bkstan\u010diams pacient\u0173 \u2013 nauji efektyv\u016bs vaistai pad\u0117s suvaldyti lig\u0105, gerinti gyvenimo kokyb\u0119\u201c, \u2013 sako Valstybin\u0117s ligoni\u0173 kasos (VLK) Vaist\u0173 kompensavimo skyriaus ved\u0117jas Evaldas Stropus.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Neilgai trukus \u012f kompensuojam\u0173j\u0173 vaist\u0173 kainyn\u0105 taip pat bus \u012ftrauktas sacituzumabas govitekanas, skiriamas agresyvesn\u0117ms kr\u016bties v\u0117\u017eio formoms gydyti, o vaist\u0173 gamintojui pasira\u0161ius sutart\u012f su VLK \u2013 tukatinibas, skiriamas nei\u0161operuojamo arba i\u0161plitusio kr\u016bties v\u0117\u017eio gydymui. Be to, artimiausiu metu bus prad\u0117tos pirkimo proced\u016bros \u012fsigyti centralizuotai apmokamam vaistui daunorubicinui su citarabinu, skirtam \u016bminei mieloidinei leukemijai gydyti.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Prognozuojama, kad naujiems vaistams nuo v\u0117\u017eio kompensuoti \u0161iemet papildomai bus skirta apie 19 mln. eur\u0173 PSDF biud\u017eeto l\u0117\u0161\u0173.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">VLK duomenimis, i\u0161 viso prie\u0161navikiniams vaistams kompensuoti 2024 m. i\u0161leista beveik 244 mln. eur\u0173. Tiek valstyb\u0117s l\u0117\u0161\u0173 prireik\u0117 51,6 t\u016bkst. pacient\u0173 gydymui. Pastebima, kad onkologiniams vaistams skirta suma per pastaruosius penkerius metus i\u0161augo du kartus.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><em>SAM ir VLK inf.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Privalomojo sveikatos draudimo fondo (PSDF) l\u0117\u0161omis nuo \u0161iol bus kompensuojami nauji vaistai, skirti \u012fvairi\u0173 form\u0173 v\u0117\u017eiui gydyti. \u201eSveikatos apsaugos ministerija kartu su Valstybine ligoni\u0173 kasa ir Valstybine vaist\u0173 kontrol\u0117s tarnyba deda visas pastangas, kad nauji veiksmingi vaistai nuo v\u0117\u017eio kuo grei\u010diau pasiekt\u0173 pacientus. Glaudus institucij\u0173 bendradarbiavimas padeda spar\u010diau \u012fgyvendinti teis\u0117s akt\u0173 reikalavimus ir \u012ftraukti \u0161iuos [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":8166,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-8165","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-naujienos"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.sakiaivsb.lt\/index.php?rest_route=\/wp\/v2\/posts\/8165","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sakiaivsb.lt\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.sakiaivsb.lt\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.sakiaivsb.lt\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.sakiaivsb.lt\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=8165"}],"version-history":[{"count":1,"href":"https:\/\/www.sakiaivsb.lt\/index.php?rest_route=\/wp\/v2\/posts\/8165\/revisions"}],"predecessor-version":[{"id":8167,"href":"https:\/\/www.sakiaivsb.lt\/index.php?rest_route=\/wp\/v2\/posts\/8165\/revisions\/8167"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.sakiaivsb.lt\/index.php?rest_route=\/wp\/v2\/media\/8166"}],"wp:attachment":[{"href":"https:\/\/www.sakiaivsb.lt\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=8165"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sakiaivsb.lt\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=8165"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.sakiaivsb.lt\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=8165"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}